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Running title: Role of the Arf6–MKLP1 complex in cytokinesis 
 2 
A small GTPase, Arf6, is involved in cytokinesis by localizing to the Flemming body (the 
midbody). However, it remains unknown how Arf6 contributes to cytokinesis. Here we demonstrate 
that Arf6 directly interacts with mitotic kinesin-like protein 1 (MKLP1), a Flemming body−localizing 
protein essential for cytokinesis. The crystal structure of the Arf6−MKLP1 complex reveals that 
MKLP1 forms a homodimer flanked by two Arf6 molecules, forming a 2:2 heterotetramer containing 
an extended β-sheet composed of 22 β-strands that spans the entire heterotetramer, suitable for 
interaction with a concave membrane surface at the cleavage furrow. We show that, during 
cytokinesis, Arf6 is first accumulated around the cleavage furrow and, prior to abscission, recruited 
onto the Flemming body via interaction with MKLP1. We also show by structure-based mutagenesis 
and siRNA-mediated knockdowns that the complex formation is required for completion of 
cytokinesis. A model based on these results suggests that the Arf6−MKLP1 complex plays a crucial 
role in cytokinesis by connecting the microtubule bundle and membranes at the cleavage plane.
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Cytokinesis is the final stage of cell division, during which cells exhibit drastic morphological changes and 
remodeling of the cytoskeleton (Balasubramanian et al, 2004; Glotzer, 2005). In anaphase/telophase, an 
actomyosin contractile ring constricts the plasma membrane in the equatorial region of a dividing cell to 
form a cleavage furrow, while an overlapping region of antiparallel microtubules from the central spindle 
gradually forms a dense structure, the Flemming body, in the middle of the intercellular bridge (Note that, 
although this dense structure is often referred to as the midbody, we hereafter refer to it as the Flemming 
body to avoid confusion between the terms ‘midbody’, the entire central spindle, and midbody 
microtubules). Finally, the cell undergoes abscission on either side of the Flemming body to generate two 
daughter cells. The drastic shape changes and membrane fission event during cytokinesis entail local 
delivery and/or removal of membranes and specific proteins (Prekeris & Gould, 2008; Steigemann & 
Gerlich, 2009). For example, proteins involved in membrane tethering, fusion and fission, such as exocyst 
components, SNARE proteins and ESCRT subunits, accumulate around the intercellular bridge and the 
Flemming body (Neto et al, 2011; Prekeris & Gould, 2008). Furthermore, coordination of changes in the 
organization of membranes and cytoskeleton suggests that interactions occur between components of the 
membrane trafficking and cytoskeleton remodeling machineries. 
Members of the Arf (ADP-ribosylation factor) family of small GTPases regulate various aspects 
of membrane traffic. Mammals have six Arf isoforms, which are divided into three classes based on 
sequence similarity (Kahn et al, 2006): class I, Arf1−Arf3 (humans lack Arf2); class II, Arf4 and Arf5; and 
class III, Arf6. Arf6 is divergent from Arf1−Arf5, and localizes to the plasma membrane and the endocytic 
system, where it regulates endosome recycling and remodeling of actin and membranes (D'Souza-Schorey 
& Chavrier, 2006). In addition to these roles in interphase cells, Arf6 has been suggested to be required for 
the final phase of cytokinesis in mammalian cells (Schweitzer & D'Souza-Schorey, 2002; Schweitzer & 
D'Souza-Schorey, 2005). Furthermore, a Drosophila arf6 mutant exhibits male sterility due to a cytokinesis 
defect during spermatocyte meiosis, although somatic cell mitosis appears to be normal (Dyer et al, 2007). 
During cytokinesis, Arf6 transiently localizes to the Flemming body; however, the molecular 
mechanism underlying its targeting remains controversial. The roles of FIP3 and FIP4 (Rab11 
family−interacting protein 3 and 4), which are dual effectors of Rab11 and Arf6 and associate with recycling 
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endosomes in interphase cells, are the subject of debate. One previous study suggested that Arf6 is recruited 
to the Flemming body independently of Rab11- and FIP3-containing endosomes (Fielding et al, 2005), 
whereas other studies have proposed that Arf6 requires an interaction with Rab11- and FIP3-positive 
endosomes to be targeted to the cleavage furrow (Montagnac et al, 2009; Schonteich et al, 2007). 
In the course of our previous study on the roles of Rab11 and Arf6 in the localization of FIP3 
during cytokinesis, we obtained evidence indicating that Arf6 is recruited onto the Flemming body 
independently of Rab11 and FIP3 (Takahashi et al, 2011). In this study, we extend these observations to 
show that Arf6 targeting to the Flemming body depends on its direct binding to MKLP1 (mitotic 
kinesin-like protein 1; also known as KIF23), which together with MgcRacGAP/Cyk4 constitutes the 
centralspindlin complex at the Flemming body (Balasubramanian et al, 2004; Glotzer, 2005). We have 
determined the crystal structure of a complex between the MKLP1 C-terminal domain and Arf6, revealing a 
unique extended β-sheet of 22 strands that spans the entire 2:2 Arf6−MKLP1 complex. This interaction of 
MKLP1 with Arf6 is unique among Arf−effector interactions. Structure-based mutagenesis and 
siRNA-mediated knockdowns allowed us to critically test models of Arf6 recruitment to the Flemming body. 




Specific association of GTP-bound Arf6 to the Flemming body 
As a first step toward characterizing the specific localization of Arf6 to the Flemming body, we 
examined the localization of Arf proteins during cytokinesis in HeLa cells (Figure 1A, B). C-terminally 
mCherry-tagged Arf6 exhibited a distinct localization to the Flemming body in a late phase of cytokinesis, 
whereas no such Flemming body localization of other Arf proteins examined (Arf1, Arf3 and Arf5) was 
evident. At high levels of expression of Arf1-mCherry, however, a weak signal could be seen at the 
Flemming body. We next asked whether the activation status of Arf6 was critical for localization at the 
Flemming body. In order to address this issue, we took advantage of the dominant activating and 
inactivating mutants, respectively, Arf6(Q67L) and Arf6(T27N) (Figure 1C, D). Both the wild type (top 
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row) and activated Arf6 mutant (middle row) localized to the Flemming body. In contrast, Arf6(T27N), 
which is a nucleotide-free form (Macia et al, 2004), exhibited little or no staining at the Flemming body 
(bottom row). 
We next examined spatiotemporal changes in the localization of Arf6 during mitosis, using 
three-dimensional time-lapse imaging to follow Arf6-EGFP expressed in HeLa cells (Figure 1E and Movie 
S1). In metaphase, when the cells were nearly spherical, Arf6-EGFP was uniformly distributed throughout 
the cytoplasm (Figure 1E, top panels (0:00), the dividing cell marked by a yellow asterisk). At the onset of 
cytokinesis, Arf6-EGFP transiently accumulated at the ingressing cleavage furrow (0:35, cyan arrow). 
Three-dimensional image analysis of fixed cells suggested that Arf6-EGFP is localized in the cortical region 
of the cleavage plane but not on the central spindle (Movie S2). Arf6-EGFP then became increasingly 
concentrated at the Flemming body as cytokinesis proceeded (Figure 1E, green arrows). Upon abscission, 
Arf6-EGFP was incorporated into one of the daughter cells as a Flemming body remnant (3:40, red arrows 
in the cell with a magenta asterisk; 6:00, in the cell with a yellow asterisk). Intriguingly, the Flemming body 
remnant subsequently crawled up along the cortical surface of the daughter cell (4:30 and 6:00, red arrows in 
the cells with magenta asterisks) (see Discussion). 
Phenotype of Arf6-knockout cells 
Two different laboratories have published studies using Arf6 siRNAs, but their experiments yielded 
contradictory results: one study showed that Arf6-knockdown cells exhibited a two-fold increase in the 
percentage of binucleate cells (Schweitzer & D'Souza-Schorey, 2005), whereas the other study showed that 
a similar siRNA treatment did not change the number of binucleate cells (Yu et al, 2007). To circumvent 
problems inherent to the siRNA approach (i.e., incomplete protein depletion and off-target effects), we 
exploited mouse embryonic fibroblasts (MEFs) established from an Arf6-knockout (KO) mouse (Suzuki et 
al, 2006) to evaluate the role of Arf6 in cytokinesis. As shown in Figure 1F, multinucleate cells (cells with 
≥3 nuclei) were observed in a fraction of Arf6-KO MEFs. Counting the numbers of both binucleate and 
multinucleate cells revealed that, as compared with wild-type MEFs, Arf6-KO MEFs frequently exhibited a 
multinucleate phenotype indicative of failed cytokinesis (Figure 1G); note that, the percentage of 
multinucleate cells might be underestimated because cytokinesis failure potentially reduces cell viability. 
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Taken together, these data indicate that Arf6 contributes to cytokinesis. 
Characterization of the Arf6−MKLP1 interaction 
Approximately a dozen years ago, Boman et al. reported that Arf isoforms interacted with MKLP1 
in the yeast two-hybrid system (Boman et al, 1999). MKLP1 constitutes the centralspindlin complex 
together with MgcRacGAP/Cyk4 and plays an essential role in cytokinesis by localizing to the Flemming 
body (Glotzer, 2005; Matuliene & Kuriyama, 2002; Mishima et al, 2002). However, the physiological 
relevance of this interaction has never been clearly established. Given the Flemming body localization of 
Arf6, its direct binding to MKLP1, and the role of MKLP1 in the centralspindlin complex, we set out to 
reevaluate the functional implications of the Arf6−MKLP1 interaction. 
In humans, there are two splice variants of MKLP1 (Figure 2A); a longer form of 960 amino acids, 
and a shorter form of 856 amino acids that lacks residues 690−793 of the longer one. We used the shorter 
form in the following experiments because our preliminary experiments indicated that it is predominant in 
HeLa cells; the region missing in the shorter form is dispensable for the MKLP1 interaction with Arf6 (see 
below); and each form localizes to the Flemming body. Hereafter, residue numbering corresponds to the 
sequence of the shorter form. 
We found that a region near the C-terminus of MKLP1 was necessary and sufficient for binding to 
Arf6; residues 690−807 of MKLP1 are required for binding to Arf6(Q67L), as the 118-residue region fused 
to GST was sufficient to specifically pull down Arf6(Q67L)-HA from solution. C-terminal truncation of this 
domain by only 18 residues (MKLP1(690−789)) abolished the ability to pull down Arf6(Q67L)-HA, 
suggesting a particularly important role for the C-terminal peptide region (Figure 2B). This result was 
unexpected, because Boman et al. (1999) reported that the region of MKLP1 C-terminal to residue 720 was 
dispensable for the interaction with Arf proteins in yeast two-hybrid assays (discussed below). The 
Arf-binding domain of MKLP1 (residues 690−807; hereafter referred to as cMKLP1) was sufficient to pull 
down wild-type Arf6 or Arf6(Q67L), but not Arf6(T27N) (Figure 2C). This domain also interacted with all 
Arf isoforms examined (Arf1, Arf3, Arf5 and Arf6) when they were expressed in HeLa cells as 
constitutively activated proteins (Figure 2D). In addition, surface plasmon resonance (SPR) measurements 
revealed that cMKLP1 showed the highest affinity to Arf6 (with a Kd value of 16 µM) among the Arf 
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isoforms examined (Figure 2E); the Kd values of Arf1, Arf3 and Arf5 were 120, 87 and 120 µM, 
respectively. 
Characterization of Arf6 and MKLP1 on the Flemming body 
Next, we compared the localization of endogenous Arf6 and MKLP1 by immunofluorescence 
analysis. In the majority of cells during cytokinesis, Arf6 and MKLP1 were colocalized at the Flemming 
body (Figure 3A, lower row). However, some cells exhibited MKLP1, but not Arf6, on the Flemming body 
(upper row). After closer examination of this variability in results, we noted a strong correlation between the 
presence of a relatively thick central spindle, suggestive of an earlier phase of cytokinesis, and the absence of 
Arf6 colocalization with MKLP1 at the Flemming body (Figure 3A, upper row, and Figure 3B). In contrast, 
cells with a relatively thin central spindle, indicating a later phase of cytokinesis, exhibited colocalization of 
MKLP1 and Arf6 (Figure 3A, lower row, and Figure 3B). These observations reveal a clear temporal 
distinction between the times at which MKLP1 and Arf6 are recruited to the Flemming body, and suggest 
that Arf6 may be recruited to the Flemming body through its binding to MKLP1. 
To begin to test this model, we next performed time-lapse analysis of cells co-expressing 
Arf6-EGFP and mRFP-MKLP1. As shown in Figure 3C and Movie S3, mRFP-MKLP1 appeared first on 
the Flemming body (for example, see 0:10). After that time point, Arf6-EGFP started accumulating around 
the ingressing cleavage furrow (0:15 and 0:20). As cytokinesis proceeded, Arf6-EGFP became colocalized 
with mRFP-MKLP1 on the Flemming body (0:30−1:10). After abscission, Arf6-EGFP and mRFP-MKLP1 
were incorporated en bloc into one of the daughter cells as a Flemming body remnant (2:00 and 3:00). The 
time-lapse data indicate that the localization of MKLP1 to the Flemming body is independent of Arf6. To 
confirm this, we examined the localization of MKLP1 in Arf6-KO MEFs (Figure 3D). MKLP1 was found 
on the Flemming body in Arf6-KO MEFs (lower row), as in wild-type MEFs (upper row), confirming 
Arf6-independent localization of MKLP1 to the Flemming body. 
Overall structure of the Arf6−MKLP1 complex 
To elucidate the molecular basis for the GTP-dependent interaction of Arf6 with MKLP1, we 
determined the crystal structure at 3.0 Å resolution of an N-terminal truncation of Arf6(Q67L) (residues 
13–175; referred to as Arf6 in the context of X-ray crystallography and small angle X-ray scattering (SAXS) 
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measurements) in complex with cMKLP1. The crystals of the Arf6−cMKLP1 complex belonged to the 
space group P21, and its overall structure is shown in Figure 4A. The asymmetric unit contains four 
Arf6−cMKLP1 complexes, which are similar to one another: Cα-atom root-mean-square deviations 
(RMSD) of four Arf6 (Arg15−Asn172)−cMKLP1 (Arg714−Pro799) complexes were between 0.21 Å and 
0.42 Å. The cMKLP1 structure is composed of five strands (β1: Trp715−His718, β2: Ala737−Val740, β3: 
Lys753−Leu761, β4: Ile767−Lys778, β5: Gln784−Lys795), one short helix (α1: Glu745−Lys750), and a 
long loop (Pro720−Val734) including the short βA region (Val729−His733) (Figure S1A), which is 
assigned to constitute a small β sheet in the cMKLP1 homodimer (Figure 4A, B). In the crystal, two 
cMKLP1 molecules form a homodimeric core held together by two layers of anti-parallel β-strand 
interactions, the major interaction between two β5-strands and the minor one between two βA-strands of 
cMKLP1 (Figure 4B). The two Arf6 molecules flank the cMKLP1 homodimer on either side, and do not 
make direct contact with each other. The overall heterotetramer is a rectangular parallelepiped with 
approximate dimensions of 51 Å × 54 Å × 96 Å (Figure 4A). One striking feature of the 2:2 Arf6−cMKLP1 
heterotetrameric complex is an extended β-sheet of 22 β-strands that spans the entire complex (Figure 4B, a 
shadowed region). The buried surface areas between Arf6 and cMKLP1, and between cMKLP1 and 
cMKLP1, are respectively 2241 Å2 (surface complementarity Sc values: 0.69) and 2080 Å2 (Sc values: 0.78) 
(Table S1). 
SAXS measurements were carried out in order to detect the formation of the Arf6−cMKLP1 
heterotetramer in solution (Figure 4C). Guinier analysis revealed that the molecular size of the 
Arf6−cMKLP1 complex changes as a function of its concentration: at higher concentrations, size increased 
gradually and eventually reached that of the heterotetramer. We also confirmed formation of the cMKLP1 
dimer in solution by chemical cross-linking experiments (Figure S2), indicating that the heterotetramer in the 
crystal reflects a form that occurs naturally in solution, rather than a crystallographic artifact. Statistics 
regarding the structure determination and its refinement are summarized in Table S2. Multiple alignment, 
secondary structure and binding sites of the solved Arf6 and cMKLP1 structures are summarized in Figure 
S1. Unless otherwise noted, we hereafter describe the structural details using chain A (Arf6) and chain B 
(cMKLP1) in the crystal. 
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Interactions between Arf6 and cMKLP1 
The interface between Arf6 and cMKLP1 in the complex (Figure 5A-C) effectively explains the 
GTP-dependence of the interaction between the two proteins (Figure 2C) (Boman et al, 1999). The 
GDP−GTP cycle of Arf6 results in significant conformational changes in the switch 1 (Sw1) and switch 2 
(Sw2) regions, as well as an additional interswitch toggle that causes a two-residue register shift (Pasqualato 
et al, 2001). In the GDP-bound state, the Sw1 region retracts, resulting in formation of a new β-strand (β2’) 
(Figure 5C) (Ménétrey et al, 2000; Pasqualato et al, 2001; Pasqualato et al, 2002). In the complex between 
GTP-bound Arf6 and MKLP1, the β2’-strand overlaps with the β5-strand of MKLP1 (Figure 5C), thus 
interfering with the β2Arf6−β5MKLP1 inter-strand interaction. 
Although the hydrophobic residues of Arf6 involved in the Arf6−cMKLP1 interaction are 
similar to those playing analogous roles in the Arf6−CTA1 and Arf6−JIP4-LZII complexes (Figure S1) 
(Isabet et al, 2009; O'Neal et al, 2005), a search of the Dali server (Holm & Rosenström, 2010) revealed no 
structures similar to that of cMKLP1. The unique structure of cMKLP1 allows hydrogen bond interactions 
between residues in the hydrophobic pocket and Phe47Arf6, Trp62Arf6 and Tyr77Arf6 (Figure 5D); these 
residues are conserved in the Arf and Rab GTPase families and are collectively called a ‘triad patch’ 
(Chavrier & Ménétrey, 2010; Kawasaki et al, 2005; Ménétrey et al, 2007; Merithew et al, 2001). First, β2Arf6 
and β5cMKLP1 make an anti-parallel inter-protein β-sheet interaction (Figure 5D, E). Val45Arf6, Phe47Arf6 and 
Val49Arf6 make main-chain hydrogen bonds with Phe788cMKLP1, Val786cMKLP1 and Gln784cMKLP1, 
respectively. There are also two side-chain hydrogen bonds (Asn48Arf6-Ser785cMKLP1 and 
Glu50Arf6-Thr779cMKLP1) on this interface. Second, His758cMKLP1 makes a hydrogen bond to His76Arf6 in the 
GTP-sensitive Sw2 (Figure 5F). In this region, the hydrophobic interface includes Leu73Arf6 and His76Arf6 
along with Pro720cMKLP1, Leu756cMKLP1, His758cMKLP1 and Ile772cMKLP1. His758cMKLP1 interacts with both 
Leu73Arf6 and His76Arf6. A third interface is present at the triad patch formed by Phe47Arf6, Trp62Arf6, and 
Tyr77Arf6. Ala743cMKLP1, Tyr754cMKLP1 and Val786cMKLP1 are involved in the interaction with the triad patch, 
with Phe47Arf6 and Tyr77Arf6 forming three hydrogen bonds with Val786cMKLP1 and Tyr754cMKLP1, 
respectively (Figure 5G). Trp62Arf6 does not engage in hydrogen bond interactions with the residues of 
effector proteins such as cMKLP1 and CTA1, with the exception of JIP4-LZII. Phe788cMKLP1 is located 
 10 
between the Sw1 and Sw2 regions, and its main chain forms a hydrogen bond with that of Val45Arf6 (Figure 
5D, E, G). The position of the Phe788cMKLP1 residue is conserved not only in various Arf effectors but also in 
Rab effectors (Kawasaki et al, 2005). 
Arf6−MKLP1 interaction is required for Arf6 localization to the Flemming body and for cytokinesis 
Based on the crystal structure, we introduced mutations into Arf6 and MKLP1 that were designed 
to perturb the Arf6−MKLP1 interaction. We focused on the hydrophilic interactions between His76Arf6 and 
His758MKLP1 and between Tyr77Arf6 and Tyr754MKLP1, because our previous structural study of Arf1 in 
complex with the GGA1-GAT domain revealed that the corresponding His and Tyr residues of Arf1 are 
critical for this interaction (Shiba et al, 2003). When assayed by pull down with GST-GGA1, GST-JIP4 or 
GST-FIP4 (Figure 6A), both H76A and Y77A mutations in Arf6(Q67L) abolished the interaction with the 
GST-fusion proteins. The Y77A mutation also abolished Arf6 binding to MKLP1, when assayed by 
pulldown with GST-cMKLP1 (Figure 6A). However, Arf6(H76A) retained binding to cMKLP1 in the same 
assay (Figure 6A). When the Y754A or H758A mutation was introduced into cMKLP1, only the former 
mutation substantially reduced the binding to Arf6 (Figure 6B). These results highlight the conclusion that 
the interaction between Tyr77Arf6 and Tyr754MKLP1 is critical to formation of the complex, while that between 
His76Arf6 and His758MKLP1 is dispensable (see Discussion). 
We then used the Arf6 and MKLP1 mutants to test whether the Arf6−MKLP1 interaction is crucial 
for targeting of Arf6 to the Flemming body (Figure 6C, D). When expressed in HeLa cells, Arf6-EGFP 
(Figure 6C, top row) and the MKLP1 binding−competent Arf6(H76A)-EGFP (middle row) both localized 
to the Flemming body, like endogenous Arf6. In contrast, the MKLP1 binding−defective Arf6(Y77A) 
mutant was unable to localize to the Flemming body (bottom row). 
We also exploited MKLP1 mutants to determine whether MKLP1 is responsible for recruiting Arf6 
to the Flemming body, and whether the loss of Arf6 recruitment is associated with any defects in cytokinesis. 
We first knocked down endogenous MKLP1 in HeLa cells using siRNAs, and examined the localization of 
Arf6. A number of control cells exhibited immunostaining for both MKLP1 and Arf6 on the Flemming 
body or its remnant (Figure 6E, upper panels; green for MKLP1, red for Arf6). Because MKLP1 is essential 
for Flemming body formation and completion of cytokinesis (Zhu et al, 2005), knockdown of MKLP1 
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abolished not only the MKLP1 signals but also the Arf6 signals on the Flemming body and its remnants, and 
increased the population of multinucleate cells (Figure 6E, lower panels, and Figure 6H). We determined 
whether exogenous expression of MKLP1 mutants restored the Flemming body localization of endogenous 
Arf6 in the context of MKLP1 knockdown (Figure 6F, G). Like wild-type MKLP1 (Figure 6F, top row), the 
Arf6 binding-competent MKLP1(H758A) mutant (bottom row) localized to the Flemming body where it 
was able to recruit Arf6. In contrast, the Arf6 binding-defective mutant, MKLP1(Y754A) (middle row), 
could not restore the Flemming body localization of Arf6, even though this mutant itself localized to the 
Flemming body and was able to recruit MgcRacGAP/Cyk4 to the Flemming body like wild-type MKLP1 
(Figure S3). In the rescue experiment, we counted the numbers of bi- and multinucleate cells. 
Co-transfection of the wild-type MKLP1 or MKLP1(H758A) vector together with the MKLP1 siRNAs 
significantly decreased the percentage of multinucleate cells (Figure 6H). In contrast, co-transfection of the 
MKLP1(Y754A) vector led to a marginal, if any, rescue of the multinucleate phenotype. These observations 
demonstrate that Arf6 must bind to MKLP1 in order to be recruited to the Flemming body. Furthermore, 
loss of Arf6 recruitment diminishes the ability to faithfully complete cytokinesis and is correlated with an 
increase in polyploidy. 
 
DISCUSSION 
In this study, we have shown that Arf6 is recruited onto the Flemming body by interacting with 
MKLP1 prior to abscission during cytokinesis. We have also revealed the molecular basis for the 
Arf6−MKLP1 interaction, and demonstrated that Arf6 and MKLP1 form a 2:2 heterotetramer containing a 
unique β-sheet composed of 22 strands that spans the entire heterotetramer. Furthermore, using mutants of 
Arf6 and MKLP1 designed on the basis of the crystal structure, we have confirmed that the Arf6−MKLP1 
interaction is crucial for proper cytokinesis. 
Targeting of Arf6 to the MKLP1-positive Flemming body and its implication in cytokinesis 
We have shown that Arf6 targeting to the Flemming body requires its interaction with MKLP1. 
Arf6 appears first to be concentrated around the ingressing cleavage furrow (Figure 1E, cyan arrow, and 
Movies S1 and S2), and is subsequently recruited onto the Flemming body, where MKLP1 has been 
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previously localized (Figure 3C and Movie S3). Together with experiments using Arf6-KO MEFs (Figure 
3D) and MKLP1 siRNAs (Figure 6E, F), these observations support a model in which Arf6 targeting to the 
Flemming body depends on MKLP1. 
MKLP1 is required for formation of the Flemming body and completion of cytokinesis (Matuliene 
& Kuriyama, 2002; Zhu et al, 2005). In HeLa cells depleted of MKLP1, not only MKLP1 signals but also 
Arf6 signals on the Flemming body and its remnants disappear (Figure 6E); the population of multinucleate 
cells is increased as compared with control siRNA-treated cells (Figure 6H). Both the Arf6 delocalization 
and multinucleate phenotype are significantly rescued by exogenous expression of MKLP1(WT) or 
MKLP1(H758A), which retains the Arf6 binding ability. By contrast, expression of the Arf6 
binding−defective mutant MKLP1(Y754A) apparently does not restore localization of Arf6 to the 
Flemming body and marginally rescues the multinucleate phenotype (Figure 6F-H). 
The transient association of Arf6 with the cleavage furrow prior to its attachment to the Flemming 
body (Figures 1E and 3C, and Movies S1-S3) suggests that Arf6 is activated in a spatially specific manner 
when it is near the cleavage furrow. In this context, it is noteworthy that PtdIns4P 5-kinase and its product, 
PtdIns(4,5)P2, accumulate near the cleavage furrow during cytokinesis (Emoto et al, 2005; Field et al, 2005). 
Previously, we showed that Arf6 can directly activate PtdIns4P 5-kinase (Honda et al, 1999). Because 
several Arf guanine-nucleotide exchange factors, including EFA6 (exchange factor for Arf6), have PH 
domains that bind PtdIns(4,5)P2 (Derrien et al, 2002; Klarlund et al, 2000), Arf6 can be locally activated by 
these exchange factors. Thus, it is possible that a small increase in activated Arf6 leads to an amplification in 
the signal through a localized increase in the phosphoinositide. 
How does Arf6 regulate cytokinesis? Arf6 may mediate, by vesicular transport, local delivery of 
membranes and specific proteins such as the exocyst complex, which allows targeting of vesicles to the 
plasma membrane domains where ingression and abscission occur (Prekeris & Gould, 2008; Steigemann & 
Gerlich, 2009). Arf6’s role in cytokinesis may be primarily a matter of fine-tuning, since Arf6-KO MEFs 
retain the capacity for division, although the population of multinucleate cells is elevated. 
Comparison of interfaces between GTP-bound Arf6 and effector proteins 
The overall structure of the Arf6−cMKLP1 complex, including the β-sheet extending throughout 
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the complex, is unique among Arf−effector complexes. However, comparison between the Arf6−cMKLP1 
complex and two Arf6−effector complexes, Arf6−CTA1 and Arf6−JIP4-LZII, whose structures have 
already been solved (Isabet et al, 2009; O'Neal et al, 2005), reveals some intriguing similarities (Figure 7A). 
First, the overall structures of Arf6 in complex with these effectors, as well as the monomeric Arf6−GTPγS 
structure (PDB 2J5X), are quite similar to one another, with an RMSD of 0.42 Å over all the Cα atoms. 
Thus, MKLP1 binding, or binding of effectors in general, does not significantly affect the conformation of 
the activated GTPase. Second, the same interface of Arf6, involving the Sw1, Sw2 and interswitch regions, 
is employed not only in its complex with cMKLP1 but also in its complexes with CTA1 and JIP4-LZII 
(Figures 5A and 7A), with the surface areas varying from 1658 Å2 (Arf6−JIP4-LZII) to 2241 Å2 
(Arf6−cMKLP1) (Table S1). The corresponding surface regions of Arf1 and Arl (Arf-like) GTPases are also 
engaged in formation of complexes with their effectors (Figure 7B) (Hanzal-Bayer et al, 2002; Kawasaki et 
al, 2005; Panic et al, 2003; Shiba et al, 2003; Zhang et al, 2009). The interfaces between Arf/Arl molecules 
and their effectors include invariant hydrophobic residues that constitute the hydrophobic pocket, as well as 
the triad patch involved in effector binding (Chavrier & Ménétrey, 2010; Kawasaki et al, 2005; Ménétrey et 
al, 2007). In the Arf6−cMKLP1, Arf6−CTA1 and Arf6−JIP4-LZII complexes, these hydrophobic residues 
of Arf6 are largely conserved (Figures 5D and S2B). 
Despite the extensive conservation of Arf6 residues involved in its interaction with effector proteins, 
the effector structures are quite different from one another (Figures 5A and 7A). The CTA1 interface 
includes an activation loop between an α-helix and a β-sheet (Kawasaki et al, 2005; O'Neal et al, 2005), and 
JIP4−LZII forms an all-helical homodimer that constitutes the interface for Arf6 (Isabet et al, 2009). The 
cMKLP1 interface is mainly composed of five β strands (Figures 4B and 5A). The two hydrogen bonds 
between Phe47Arf6 within β2 and Val786cMKLP1 within β5 make major contributions to the β-strand 
interaction (Figure 5E, G). In contrast, Phe47Arf6 forms a water-mediated hydrogen bond with Gly118CTA1 
and a hydrogen bond with Lys423JIP4 in only one (chains A/C) of the two complexes in the crystal (Isabet et 
al, 2009; O'Neal et al, 2005). 
We have shown that the interaction between Tyr77Arf6 and Tyr754cMKLP1 is more critical for the 
formation and function of the Arf6−cMKLP1 complex than that between His76Arf6 and His758cMKLP1 (Figure 
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6). Tyr77Arf6 is assigned as one of the key residues in the invariant hydrophobic triad (Figure 5D) (Chavrier 
& Ménétrey, 2010; Kawasaki et al, 2005; Ménétrey et al, 2007) and participates in direct hydrogen bond 
formation in the Arf6−cMKLP1 complex (the distance between OH atom of Tyr77Arf6 and OH atom of 
Tyr754cMKLP1 is 2.8 Å) (Figure 7C, left), whereas it makes a water-mediated hydrogen bond with Pro92CTA1 
or Asp419JIP4. His76Arf6 that has been identified as a residue of the hydrophobic pocket (Chavrier & 
Ménétrey, 2010; Kawasaki et al, 2005; Ménétrey et al, 2007) contributes less significantly to the cMKLP1 
interaction than does Tyr77Arf6. However, His76Arf6 is indeed important for interactions with other effectors; 
it is one of the residues that form an effector-binding patch in the Arf6−CTA1 complex (O'Neal et al, 2005), 
and its carbonyl main chain forms an additional hydrogen bond to Lys417JIP4 to further stabilize the 
Arf6−JIP4-LZII complex (Isabet et al, 2009). His76Arf6 (His80Arf1) is critical for the Arf interaction with the 
GGA1-GAT domain (Figure 7C, right). Superimposing the Arf6 structure on the Arf1−GGA1 complex 
(PDB 1J2J) (Shiba et al, 2003) reveals that His76Arf6 forms a water-mediated hydrogen bond with 
Ser175GGA1, whereas Tyr77Arf6 can interact with GGA1 only through van der Waals contacts (Figure 7C, 
right). Thus, when His76Arf6 is mutated, the van der Waals contacts of Tyr77Arf6 are not sufficient to maintain 
the Arf6−GGA1 complex. By contrast, in the Arf6−cMKLP1 complex, His76Arf6 forms a hydrogen bond 
with His758cMKLP1, whereas Tyr77Arf6 interacts with cMKLP1 through a hydrogen bond with Tyr754cMKLP1 
and through van der Waals contacts. It is therefore likely that the Tyr77Arf6−Tyr754cMKLP1 interaction is able 
to maintain the Arf6−cMKLP1 complex in the absence of the His76Arf6−His785cMKLP1 interaction (Figure 6A, 
B).  
We then compared the Arf6–cMKLP1 structure with that of the Arl2–PDEδ complex 
(Hanzal-Bayer et al, 2002). Although β-sheet interactions contribute to formation of both complexes, a 
parallel β-sheet is formed in the Arl2–PDEδ complex (β2Arl2–β7PDEδ) (Figure 7B), while an antiparallel one 
in Arf6–cMKLP1 (β2Arf6–β5cMKLP1) (Figure 5). Furthermore, the residue that corresponds to His76Arf6 is 
conserved in all Arfs, but not in Arl proteins, including Arl2 (Figure S1B). In the crystal structures, Asn79Arl2 
(corresponding to the His76Arf6 position) has hydrophobic interactions with Phe96PDEδ and Ile98PDEδ, and 
Tyr80Arl2 (corresponding to Tyr77Arf6) makes a hydrogen bond with the main-chain of Phe96PDEδ. Overall, 
the molecular basis for the complex formation of Arf6–cMKLP1 is different from that of Arl2–PDEδ. 
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Model for function of the Arf6−MKLP1 complex 
We propose that two molecules of activated Arf6 bind to each homodimer of MKLP1 at the 
Flemming body, resulting in a higher fidelity of cytokinesis. In the crystal, the Arf6−MKLP1 complex 
consists of a heterotetramer with two Arf6 and two MKLP1 molecules (Figure 4A). Our SAXS (Figure 4C) 
and cross-linking data (Figure S2) support the conclusion that the heterotetramer is present in solution and is 
not a crystallographic artifact. We speculate that the heterotetrameric Arf6−MKLP1 complex is anchored to 
membranes, most likely the plasma membrane, through myristoylated N-terminal helices of the two Arf6 
molecules (Figure 8A). Note that each of the Arf6 molecules in the heterotetramer are positioned such that 
their N-terminal helices and covalently attached myristates, each of which are involved in membrane 
binding, are optimally positioned, pointed away from the rest of the MKLP1 molecule and toward a 
membrane anchoring site for the activated GTPase. This model suggests that on the Flemming body, Arf6 
and the C-terminal domain of MKLP1 are positioned close to the membrane, while the N-terminal motor 
domain associates with the microtubule bundle (Figure 8A). The simultaneous association of the 
Arf6−MKLP1 complex with the microtubule bundle and the plasma membrane is indirectly supported by 
the observation that, after abscission, the Flemming body remnant migrates up along (probably beneath) the 
cortical membrane of a daughter cell (Figure 1E, red arrows, and Movie S1). The electrostatic surface 
potential map indicates that Arf6 binding to cMKLP1 enlarges its positively charged surface area relative to 
cMKLP1 alone (Figure 8B, top panels), making more favorable the association between the positively 
charged protein surface and negatively charged membrane surface. In this context, it is noteworthy that, as 
described above, PtdIns(4,5)P2 accumulates around the cleavage furrow during cytokinesis (Emoto et al, 
2005; Field et al, 2005). It will be therefore important to address whether membrane association of the 
Arf6−MKLP1 complex is under the regulation of changes in the local lipid composition. 
There is another possible function of Arf6 at the Flemming body, although not mutually exclusive 
with the above model. We previously showed that Arf6-depleted cells accumulate FIP3-positive vesicles 
around the central spindle in early cytokinesis phase, but then failed to proceed with cytokinesis (Takahashi 
et al, 2011). On the other hand, Montagnac et al. (2009) have proposed that FIP3-positive endosomal 
vesicles are trafficked towards the plus ends of the central spindle in a kinesin-1/JIP4-dependent manner. 
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Together with the results in the present study, it is therefore possible that, through interacting with FIP3/4 or 
JIP3/4, Arf6 at the Flemming body serves as an acceptor for incoming endosomal vesicles, the accumulation 
of which is required for subsequent abscission (Prekeris & Gould, 2008; Schiel et al, 2011; Steigemann & 
Gerlich, 2009). We previously showed that, after abscission, FIP3 as well as Arf6 is incorporated into one of 
the daughter cells as a Flemming body remnant (Takahashi et al, 2011), supporting an interaction of FIP3 
with Arf6 on the Flemming body. However, because an Arf6 molecule is unlikely to bind simultaneously to 
MKLP1 and FIP3/4 or JIP3/4, this model requires local switching of the Arf6 partners. 
 
MATERIALS AND METHODS 
Cell culture, DNA transfection, and RNA interference 
MEFs were established from wild-type and Arf6-KO mice (Suzuki et al, 2006). Knockdown of 
MKLP1 was performed in a previously described manner (Ishizaki et al, 2008; Man et al, 2011). Briefly, a 
3’-untranslated region of human MKLP1 cDNA was amplified using a primer set 
(5’-GCCATGAACTGACAGTCCCAG-3’ and 5’-AGTGCTTTTGATTTTAATTCTTTTGG-3’) and used 
for preparation of a pool of siRNAs with BLOCK-iT RNAi TOPO Transcription and Dicer RNAi kits 
(Invitrogen). HeLa cells grown on coverslips in a 3.5-cm dish were transfected with siRNAs (0.25 µg/dish) 
using Lipofectamine 2000 (Invitrogen) and incubated for 4 hr. The medium was then changed, and 48 hr 
after transfection the cells were processed for immunofluorescence and immunoblot analyses. For recovery 
experiments, a pCAG vector for HA-MKLP1 (0.4 µg/dish) was transfected into cells along with the 
siRNAs. 
Pulldown assay 
Escherichia coli BL21(DE3) cells transformed with the GST fusion protein vector were treated with 0.1 
mM IPTG for 4 hr at 25°C to induce protein expression, lysed and used to purify the recombinant protein 
with glutathione−Sepharose 4B beads (GE Healthcare). Lysates of HeLa cells expressing HA-tagged Arf 
were prepared as described previously (Man et al, 2011; Shiba et al, 2006; Takatsu et al, 2002) and 
incubated at 4°C for 2 hr with the GST-fusion protein coupled to glutathione–Sepharose 4B beads. The 
beads were washed four times with Hepes-based buffer, and subjected to SDS–PAGE and immunoblotting. 
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Immunofluorescence microscopy and time-lapse imaging 
For immunofluorescence microscopy, cells were fixed, permeabilized and immunostained as 
described previously (Ishizaki et al, 2008; Shin et al, 2004; Takahashi et al, 2011). For time-lapse imaging, 
cells were placed on a microscope stage that had been pre-warmed at 37°C in a 5% CO2 atmosphere. The 
cells were observed using EM-CCDs (Hamamatsu Photonics) on an Axiovert 200M microscope (Carl 
Zeiss). Images were acquired sequentially every 5 min and analyzed using IP-Lab™ ver. 4.0.8 (SOLUTION 
Systems). Three-dimensional time-lapse imaging was performed using an A1RMP confocal microscope 
(Nikon). 
Crystallization and data collection 
Crystallization conditions were initially searched using a crystallization robot (Hiraki et al, 2006). 
The final crystallization conditions for the native and Se-Met cMKLP1−Arf6 complexes were 12% w/v 
PEG 4000, 0.1 M sodium cacodylate, pH 6.5, 50 mM (NH4)2SO4, 5 mM MgCl2, 0.25-1.0% v/v ethyl acetate 
at 20°C. Crystals were then transferred to cryosolutions containing 20% glycerol or ethylene glycol. Data 
were collected at 100 K using beamline BL-5A or AR-NW12A at the Photon Factory, KEK (Tsukuba, 
Japan). All diffraction data were processed using HKL2000 (Otwinowski & Minor, 1997). Data collection 
and processing statistics are summarized in Table S2. 
Phasing, model building and refinement 
The MR-SAD method was applied to solving the Se-Met data of the Arf6−cMKLP1 complex 
(Schuermann & Tanner, 2003). An Arf6 structure (PDB 2J5X) was used as a molecular replacement (MR) 
template. The MR analysis was performed using Phaser (CCP4, 1994). The initial model was built using 
Buccaneer (CCP4, 1994) after density modification by DM or Parrot (CCP4, 1994). MR was applied to the 
native data using the Arf6−cMKLP1 complex structure generated from the Se-Met data, using Phaser. NCS 
restraints were applied during refinement before the final refinement. The final model was built with Coot 
(Emsley et al, 2010) and refined using Phenix (Adams et al, 2010) and REFMAC5 (CCP4, 1994) with TLS 
(Painter & Merritt, 2006) (Figure S5) at 3.0 Å resolution. There are four Arf6 (chains A, C, E, and 
G)−cMKLP1 (chains B, D, F, and H) complexes in the asymmetric unit. Finally, the refined structure of the 
Arf6−cMKLP1 complex was validated by MolProbity (Chen et al, 2010). The refinement statistics are 
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summarized in Table S1. Figures were drawn using MOLSCRIPT (Kraulis, 1991), Raster3D (Merritt & 
Bacon, 1997) , Pymol (Schrodinger, 2010) and CCP4MG (Potterton et al, 2004). 
SAXS experiments 
SAXS data were collected at BL-10C at the Photon Factory, KEK using bovine serum albumin 
(BSA) as a calibration standard. Arf6−cMKLP1 and BSA were dissolved in Buffer A. Protein 
concentrations varied within a range of 2.0−21.3 mg/ml. The sample cell was 50 µl in volume and had a 1 
mm path-length. The X-ray wavelength was 1.488 Å, and the scattered X-rays were recorded by PSPC with 
an exposure of 600 sec at 900 mm from the sample position. Guinier analysis was carried out by the 
standard procedure (Guinier & Fournet, 1955). Data processing was performed using the IGOR Pro data 
analysis program (Wavemetrics). X-ray scattering intensities in the small-angle region are given as I (Q) = 
I(0) exp (−Rg2Q2/3), where Q and I(0) are momentum transfer and the intensity at zero scattering angle, 
respectively. Q is defined by Q = 4πsinθ/λ, where 2θ and λ are the scattering angle and the wavelength of the 
X-rays, respectively. The radius of gyration (Rg) was obtained from the slope of the Guinier plot, which is a 
plot of ln[I(Q)] against Q2. 
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Figure 1. Localization of Arf6 to the Flemming body and phenotype of Arf6-KO cells 
 (A) HeLa cells transfected with an expression vector for C-terminally mCherry-tagged Arf1, 
Arf3, Arf5 or Arf6 were stained with anti-β-tubulin antibody. (B) The cells in late cytokinesis phase in the 
experiment shown in (A) were classified as those with and without Arf-mCherry signals at the Flemming 
body. Percentages of cells with Arf signals at the Flemming body are expressed as bar graphs. (C) HeLa 
cells transfected with an expression vector for C-terminally EGFP-tagged Arf6(WT), Arf6(Q67L) or 
Arf6(T27N) were immunostained for β-tubulin. (D) The cells in late cytokinesis phase in the experiment 
shown in (C) were classified as those with and without Arf6-EGFP signals at the Flemming body. 
Percentages of cells with Arf6-EGFP signals are expressed as bar graphs. (E) Images from a 
three-dimensional time-lapse series of HeLa cells expressing Arf6-EGFP. HeLa cells transfected with an 
expression vector for Arf6-EGFP were subjected to three-dimensional time-lapse recording. Representative 
images from Movie S1 are shown. Left and right images, rotated by 90° with respect to the z axis, show the 
same two cells (cells identified by yellow and magenta asterisks). Cyan, green and red arrows indicate 
Arf6-EGFP signals on the cleavage furrow, Flemming body and its remnant, respectively. (F) Multinucleate 
phenotype of Arf6-KO MEFs. Wild-type or Arf6-KO MEFs were stained with anti-β-tubulin to reveal 
microtubules (red) and SYTOX Green to reveal nuclei. (G) Increase in the population of multinucleate cells 
by Arf6 knockout. The cells in the experiment shown in (F) were classified as mono-, bi-, and multinucleate 
(≥3 nuclei), and counted. Percentages of bi- and multinucleate cells in four independent examinations are 
expressed as bar graphs. In (A), (C) and (F); bars, 10 µm. 
 
Figure 2. Interaction of MKLP1 with Arf6 in vitro 
 (A) Domain organization and comparison of the structures of the long and short forms of 
MKLP1. (B) A MKLP1 region encompassing residues 690−807 is responsible for interaction with Arf6. 
Lysates of HeLa cells expressing C-terminally HA-tagged Arf6(Q67L) were pulled down with GST, 
GST-MKLP1(690-807) (cMKLP1) or GST-MKLP1(690-789) and subjected to immunoblotting with 
anti-HA antibody. (C) GTP-bound Arf6 interacts with MKLP1. Lysates of HeLa cells expressing 
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C-terminally HA-tagged Arf6(WT), Arf6(Q67L), or Arf6(T27N) were pulled down with GST or 
GST-cMKLP1 and subjected to immunoblotting with anti-HA antibody. (D) MKLP1 interacts with all Arf 
isoforms examined. Lysates of HeLa cells expressing C-terminally HA-tagged Arf1(Q71L), Arf3(Q71L), 
Arf5(Q71L), or Arf6(Q67L) were pulled down with GST or GST-cMKLP1 and subjected to 
immunoblotting with anti-HA antibody. (E) SPR analysis of the GST-cMKLP1 interaction with Arf1, Arf3, 
Arf5 or Arf6. Steady-state resonance (Req) levels were plotted against each Arf concentration. Kd values 
were calculated from the fitted curves. 
 
Figure 3. Colocalization of Arf6 and MKLP1 on the Flemming body and Arf6-independent 
localization of MKLP1 
(A) Localization of endogenous Arf6 and MKLP1 during cytokinesis. HeLa cells were processed for triple 
immunostaining for Arf6, MKLP1 and α-tubulin. Note that Arf6 was found on the Flemming body in cells 
in later phase of cytokinesis (lower row), but not in early phase (upper row), as judged by the width of the 
central spindle. (B) The cells in early and late cytokinesis phases in the examination shown in (A) were 
classified as those with and without Arf6 signals at the Flemming body. Percentages of cells with 
Arf6-EGFP signals are expressed as bar graphs. (C) A time-lapse analysis of HeLa cells expressing 
Arf6-EGFP and mRFP-MKLP1. An image sequence from Movie S3 is shown. HeLa cells transfected with 
expression vectors for Arf6-EGFP and mRFP-MKLP1 were subjected to time-lapse recording. (D) Normal 
Flemming body localization of MKLP1 in Arf6-KO cells. Wild-type or Arf6-KO MEFs were doubly 
immunostained for MKLP1 and β-tubulin. In (A) and (D); bars, 10 µm. 
 
Figure 4. Overall structure and SAXS experiments of the Arf6−cMKLP1 complex 
(A) Cartoon representation of the heterotetrameric Arf6−cMKLP1 complex is shown in two 
orthogonal views (side and bottom views). The two Arf6 molecules are colored in yellow and pink, and the 
two cMKLP1 molecules colored in orange and green. The βA region is colored in royal blue. In each Arf6 
molecule, a GTP molecule and Mg2+ are rendered using ball and stick representations. (B) Schematic 
representation of the heterotetrameric Arf6−cMKLP1 complex structure. Arf6 and cMKLP1 proteins are 
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colored in the same way as in (A). In Arf6, Sw1, interswitch and Sw2 regions were colored in purple, red, 
and cyan, respectively. One Arf6−cMKLP1 complex is indicated by a dashed line enclosure. The region 
shaded in grey shows the inter-protein β-sheet extending the entire Arf6−cMKLP1 complex. The βA-region 
colored in royal blue is represented as making a small β-sheet in the heterotetrameric Arf6−cMKLP1 
complex structure. (C) Results of SAXS measurements of the Arf6−cMKLP1 complex. Guinier analysis 
shows that the values of Rg and I(0) increase as a function of the protein concentration. At the lowest 
concentration, the apparent molecular weight of the complex was estimated to be 26 kDa, slightly lower than 
the value (33 kDa) calculated from the amino acid sequence, still suggesting a 1:1 complex. At higher 
protein concentrations, the apparent molecular weight reaches a value approximately twice that of the 
heterodimer, indicating a 2:2 heterotetramer in solution. (left) Guinier plots of Arf6−cMKLP1 complex. 
(middle) Concentration dependence of Rg2. Rg2 for the Arf6−cMKLP1 complex was plotted against protein 
concentration. (right) Concentration dependence of I(0)/conc for the Arf6-cMKLP1 complex. 
 
Figure 5. Interaction between Arf6 and cMKLP1 in the complex 
(A) Overall structure of a heterodimeric portion of the Arf6−cMKLP1 complex. In this and 
following panels, cMKLP1 is shown in orange, and Arf6 is shown in yellow with Sw1 (purple), interswitch 
(red) and Sw2 (cyan). A GTP molecule and Mg2+ are represented by ball-and-stick models. (B) Structure of 
GTP-bound Arf6 alone, or along with β4- and β5-strands of cMKLP1. The outer portion of the switch 
region of Arf6 is enclosed by a dashed square. (C) Structure of GDP-bound Arf6 alone or along with β4- 
and β5-strands of cMKLP1. GDP-Arf6 (PDB 1E0S) is superimposed on GTP-Arf6 in the Arf6−cMKLP1 
complex. The conformational changes in the Sw1 region create an additional β-strand (β2’) in the GDP-Arf6 
structure. The β2’-strand of GDP-Arf6 overlaps with the β5-strand of cMKLP1, making it impossible for 
GDP-Arf6 to bind cMKLP1. (D) Schematic representation of the interface between Arf6 and cMKLP1. 
Boxes, arrows and lines represent helices, β-strands and loops, respectively. Phe788cMKLP1, located between 
Sw1 and Sw2, is labeled in black letters in the hexagon, and two other important residues (Tyr754cMKLP1 and 
His758cMKLP1) on β3cMKLP1 are labeled in black letters. Residues of the effector-binding patch on Arf6 are 
also labeled in black letters. The hydrophobic residues of the triad patch (Phe47Arf6, Trp62Arf6, and Tyr77Arf6) 
 31 
are labeled in black letters and underlined. (E) Interaction between β2Arf6 and β5cMKLP1. Secondary structure 
elements are drawn as cartoons and residues involved in the binding as sticks. Hydrogen bonds are 
represented as black dashed lines. (F) Interaction between His76Arf6 and His758cMKLP1. (G) Interaction 
between Tyr77Arf6 and Tyr754cMKLP1 in the hydrophobic triad patch region. 
 
Figure 6. Mutational analysis of the Arf6−MKLP1 interaction and Arf6 localization to the Flemming 
body  
(A) Tyr77 of Arf6 is important for Arf6’s interaction with MKLP1. Lysates of HeLa cells 
expressing C-terminally HA-tagged Arf6(Q67L), Arf6(Q67L/Y77A) or Arf6(Q67L/H76A) were pulled 
down with GST, GST-cMKLP1, GST-GGA1(GAT), GST-FIP4(484-613) or GST-JIP4(LZII) and 
subjected to immunoblotting with anti-HA antibody. (B) Tyr754 of MKLP1 is important for MKLP1’s 
interaction with Arf6. Lysates of HeLa cells expressing Arf6(Q67L)-HA were pulled down with GST, 
GST-GGA2(GAT), GST-FIP4(484-613), or wild type, Y754A mutant, or H758A mutant of GST-cMKLP1, 
and subjected to immunoblotting with anti-HA antibody. (C) HeLa cells transfected with an expression 
vector for Arf6(WT)-EGFP, Arf6(H76A)-EGFP or Arf6(Y77A)-EGFP were doubly stained with 
anti-MKLP1 and anti-β-tubulin. In this experiment, we used the Arf6(H76A) and Arf6(Y77A) mutants in 
the context of Q67L. (D) The cells in late cytokinesis phase in the experiment shown in (C) were classified 
as those with and without Arf6-EGFP signals at the Flemming body. Percentages of cells with Arf6-EGFP 
signals are expressed as bar graphs. (E) MKLP1-dependent localization of Arf6 to the Flemming body. 
HeLa cells treated with a pool of siRNAs for LacZ (siControl) or MKLP1 were triply immunostained for 
MKLP1 (green), Arf6 (red), and α-tubulin (blue). Note that a number of the control cells exhibit both the 
MKLP1 and Arf6 signals on the Flemming body or its remnant. (F) HeLa cells were transfected with an 
expression vector for HA-MKLP1(WT), HA-MKLP1(Y754A), or HA-MKLP1(H758A), together with 
siRNAs for MKLP1. After 48 hr, the cells were fixed and triply immunostained for HA, Arf6 and β-tubulin. 
(G) The cells in late cytokinesis phase in the experiment shown in (F) were classified as those with and 
without Arf6 signals at the Flemming body. Percentages of cells with Arf6-EGFP signals are expressed as 
bar graphs. (H) The control siRNA-treated cells and MKLP1 siRNA-treated cells with exogenous 
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expression of EGFP or an HA-MKLP1 construct in the experiment shown in (F) were classified as mono-, 
bi- and multinucleate (≥3 nuclei), and counted. Percentages of bi- and multinucleate cells are expressed as 
bar graphs. In (C), (E) and (F), bars, 10 µm. 
 
Figure 7.  Structures of complexes of Arf and Arl proteins with their effectors 
(A) Interfaces of Arf6 for CTA1 and JIP4-LZII. The orientation of the Arf6 molecule is the same 
as that in the Arf6−cMKLP1 complex (Figure 5A), and coloring of Arf6 regions and representation of a 
GTP molecule and Mg2+ are the same as in Figure 5A. CTA1 is colored in orange (left), and helices of the 
JIP4-LZII dimer are in orange and green (right). (B) Structures of Arf/Arl complexes with their effector 
proteins as indicated. The orientation of the Arf/Arl molecule is the same as in the Arf6−cMKLP1 complex 
(Figure 5A); coloring of Arf/Arl regions and representation of GTP and Mg2+ are the same as in Figure 5A. 
The effector proteins are colored in orange. (C) The interfaces between Arf6/Arf1 and cMKLP1 (left) and 
between Arf1/Arf6 and the GGA1-GAT domain (right) are shown. Arf6, Arf1, cMKLP1 and GGA1 are 
colored in yellow, green, orange and magenta, respectively. In the left panel, the Arf1 molecule in the 
Arf1−GGA1 complex (PDB 1J2J) is superimposed on Arf6 of the Arf6−cMKLP1 complex, and black 
dashed lines indicate hydrogen bonds between Arf6 and cMKLP1. In the right panel, a red ball represents a 
water molecule (Wat212), black dashed lines indicate hydrogen bonds between GGA1 and Arf1 via Wat212, 
and a yellow dashed line indicates a hydrogen bond between Arf6 and Wat212. 
 
Figure 8. Model for membrane and microtubule interactions of the Arf6−MKLP1 complex and its 
electrostatic potential 
(A) Model for simultaneous interactions of the heterotetrameric Arf6−MKLP1 complex with membrane and 
microtubules. During cytokinesis, the complex is likely to be anchored to the plasma membrane, and the 
MKLP1 motor domain is associated with microtubules of the Flemming body. MKLP1 molecules are 
colored in green, orange and royal blue. Arf6 molecules are colored in yellow and pink with schematically 
represented N-terminal helices, and their myristates are represented as doted lines. The numbered arrows 
indicate viewing directions in (B). (B) The electrostatic potential representations of MKLP1 and the 
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Supplementary Materials and Methods 
Reagents and antibodies 
Polyclonal rabbit anti-Arf6 antibody was raised as described previously (Akiyama et al, 
2010). Sources of other antibodies and reagents were: monoclonal mouse anti-Arf6 (3A-1) and 
anti-MgcRacGAP (A-6) and polyclonal rabbit anti-MKLP1 (N-19), Santa Cruz Biotechnology; 
monoclonal rat anti-α-tubulin, Abcam; monoclonal mouse anti-β-tubulin (KMX-1), Chemicon; 
monoclonal rat anti-HA (3F10), Roche Applied Science; AlexaFluor-conjugated secondary antibodies 
and SYTOX Green, Molecular Probes. 
Plasmids 
Human Arf cDNA was cloned into the pcDNA3-HAC (Hosaka et al, 1996), pEGFP-N3 
(Invitrogen), or pcDNA3-mCherry vector constructed from an mCherry vector originally provided by 
Roger Tsien (Shaner et al, 2005). Human MKLP1 cDNA was cloned into pcDNA3-mRFP provided 
by Roger Tsien or pCAG-HAN, which is derived from pCAGGS (Niwa et al, 1999). Truncated forms 
of the MKLP1 cDNA and a cDNA fragment for human JIP4-LZII (Isabet et al, 2009) were generated 
by PCR and cloned into pGEX4T-2 (GE Healthcare). Mutations were introduced into the Arf6 and 
MKLP1 cDNAs using a QuikChange Lightning Site-Directed Mutagenesis kit (Agilent Technologies). 
Expression vectors for GST-fused GGA1-GAT, GGA2-GAT and FIP4(484-613) were constructed as 
described previously (Shiba et al, 2006; Takatsu et al, 2002). 
Protein expression and purification 
 Human MKLP1 (690−807) (cMKLP1) and mouse Arf6(Q67L, 13−175) were cloned into 
pGEX-4T-2 and pET28a (Merck KGaA), respectively. GST-cMKLP1 and Arf6(Q67L)-His6 were 
co-expressed in E. coli BL21(DE3) cells at 20°C overnight. The expressed cMKLP1 protein is 
sensitive to proteases (Figure S4). Selenomethionine (Se-Met)-labeled GST-cMKLP and 
Arf6(Q67L)-His6 were co-expressed in LeMaster medium containing Se-Met (Wako Pure Chemical). 
Cells were disrupted by sonication in Buffer A (20 mM Tris-HCl pH 7.6, 5 mM MgCl2, 5 mM 
2-mercaptoethanol) containing 300 mM NaCl and protease inhibitor cocktail (Roche Applied Science). 
After centrifugation, the supernatant was applied to a glutathione-Sepharose 4B column, and the 
GST-tag was cleaved off using thrombin (GE Healthcare) at 20°C overnight. The eluate was passed 
through benzamidine-Sepharose 4FF (GE Healthcare) and glutathione-Sepharose 4B columns. Finally, 
the Arf6−cMKLP1 complex was isolated by Superdex 75 column (GE Healthcare) with Buffer A 
containing 200 mM NaCl. 
SPR measurements 
 C-terminally His6-tagged Arf1(Q71L, 18-181), Arf3(Q71L, 18-181) and Arf5(Q71L, 
18-181) were expressed in E. coli BL21(DE3) cells and purified as described above for Arf6(Q67L, 
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13-175)-His6. SPR measurements were performed using a BIAcore2000 (GE Healthcare). 
GST-cMKLP1 was captured on a CM5 sensor chip using GST capture kit (GE Healthcare). Binding of 
Arf1, Arf3, Arf5 or Arf6 to GST-cMKLP1 was analyzed at a flow rate of 20 µl min-1 at 25°C in 10 
mM HEPES, pH 7.5, 300 mM NaCl, 5 mM MgCl2 and 0.005 % Surfactant P20. The sensorgram was 
analyzed using the BIAevaluation 3.2 software. Kd values were determined using the steady-state 
affinity model by plotting resonance (Req) levels against protein concentrations.  
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Supplementary Figures 
 
Figure S1. Multiple alignments and interacting residues of MKLP1 and Arf6  
(A) Alignment of mammalian MKLP1 (KIF23) sequences. From bottom to top, aligned 
amino acid sequences of the cMKLP1 region of Homo sapiens (human), Rattus norvegicus (rat), Mus 
musculus (mouse), Cricetulus griseus (Chinese hamster) and Bos taurus (bovine). The numbers 
correspond to residue numbers of human MKLP1 (residues 690−807). Alignment was performed with 
PROBCONS (Do et al, 2005) and colored by ALINE (Bond & Schuttelkopf, 2009). Degrees of 
sequence similarity are colored from cyan to red (with low similarity cutoff = 0) in ALINE. Secondary 
structure was assigned by DSSP (Kabsch & Sander, 1983) and is colored in orange. The βA region 
colored in royal blue constitutes a small β sheet in the homodimer, but might be a part of a loop in the 
monomer. The residues involved in Arf6 binding and in cMKLP1 binding on cMKLP1 dimer interface 
are represented as tiles colored in orange and green, respectively. (B) Alignment of sequences of 
human Arf and Arl proteins. From top to bottom, aligned acid sequences of Arf6, Arf1, Arf3, Arf4, 
Arf5, Arl1, Arl2 and Arl3. The numbers correspond to residue numbers of Arf6 (residues 1−81). 
Alignment, coloring of similarity and secondary structure assignment were generated using the same 
software as in (A). Secondary structures of Arf6 are colored with purple (Sw1), red (interswitch), cyan 
(Sw2) and yellow (other regions). The Arf6 residues involved in binding to cMKLP1, CTA1 (PDB 
2A5D) or JIP4 (PDB 2W83) are represented as tiles in row above the secondary structure. The 
residues of Arf6 commonly used for binding to three effector proteins (cMKLP1, CTA1 and JIP4) are 
also represented as tiles. The orange and black tiles specify residues involved in effector binding and 
the effector-binding patch (O'Neal et al, 2005), respectively. 
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Figure S2. Chemical cross-linking of MKLP1 
cMKLP1 was expressed and purified by the same procedures used for the Arf6−cMKLP1 
complex. cMKLP1 was dissolved at a concentration of 1.0 mg/ml in 50 mM sodium phosphate, pH 
7.4, 300 mM NaCl and subjected to cross-linking using glutaraldehyde (GA) or disuccinimidyl 
glutarate (DSG). 1 µl of GA or DSG solution in dimethylformamide was added to 9 µl of the protein 
solution, yielding final concentrations of 0.01−2% or 1−5 mM, respectively. After incubation for 60 
min on ice, the unreacted cross-linking reagent was quenched by the addition of 1 M Tris-HCl, pH 7.4. 
The cross-linked proteins were analyzed by 17.5% (w/v) SDS–PAGE. 
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Figure S3. Recovery of MgcRacGAP localization to the Flemming body by exogenous expression 
of wild-type and mutant MKLP1 in MKLP1 siRNA-treated cells 
(A) MKLP1 depletion abolishes MgcRacGAP/Cyk4 localization to the Flemming body. 
HeLa cells treated with a pool of siRNAs for LacZ (siControl) or MKLP1 were triply immunostained 
for MKLP1 (green), MgcRacGAP (red), and β-tubulin (blue). Note that a number of the control cells 
exhibit both the MKLP1 and MgcRacGAP signals on the Flemming body or its remnant. (B) HeLa 
cells were transfected with an expression vector for HA-MKLP1(WT), HA-MKLP1(Y754A), or 
HA-MKLP1(H758A), together with siRNAs for MKLP1. After 48 hr, the cells were fixed and triply 
immunostained for HA, MgcRacGAP and β-tubulin. Bars, 10 µm. 
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Figure S4. Protease sensitive region of cMKLP1  
SDS−PAGE analysis of the major peak fractions from gel-filtration (Superdex 75) before 
optimizing purification of the Arf6−cMKLP1 complex (upper panel). The determined N-terminal 
sequence of the degraded cMKLP1 product (deg-MKLP1) was 710SAGDRWV (lower panel, colored 
in red). 
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Figure S5. The simulated annealing omit map of the Arf6−cMKLP1 complex and the omit 
region of MKLP1 
(A) The simulated annealing omit map (omit region is between Arg706 and Asp713 on 
cMKLP1) of the Arf6−cMKLP1 complex at 3.0 Å resolution. The map is contoured at 1.0 σ by 
CCP4MG (Potterton et al, 2004); Arf6 and cMKLP1 are represented as yellow and orange sticks, 
respectively. (B) The omit region of cMKLP1 from Arg706 to Asp713. The simulated annealing omit 
map is shown with the stick representation of cMKLP1. Although the working and free R factors were 
refined to 19.0% and 22.1%, respectively (Figure S6A and Table S2), only two cMKLP1 molecules 
have clear electron density between Asp695 to Arg707 in 2mFo-DFc map. In the third cMKLP1 
molecule, there was a low electron-density region from Asp695 to Ala698. Likewise, we could not 
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model the fourth cMKLP1 molecule due to a low electron-density region from Asp695 to Gly712. 
None of the four cMKLP1 molecules showed clear electron-density in the region from Arg707 to 
Gly712 during refinement of the electron-density map. Because the region corresponds to the 
protease-sensitive region (Figure S5), it may be flexible or susceptible to partial cleavage during the 
crystallization process. 
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Supplementary Tables  
Table S1. Buried surface area and shape complementary for effector protein and GTPase 
complex 
PDBePISA (Krissinel & Henrick, 2007) server was used to calculate buried surface area. The shape 
complementarity of two interacting molecular surfaces was determined by SC (Lawrence & Colman, 
1993). 
 Buried surface area (Å2) Sc value 
 Effector Arf/Arl Total  
cMKLP1:Arf6-GTP  
(chain A-B) 
1105.8 1135.2 2241.0 0.69 
CTA1:Arf6-GTP 
 (PDB 2A5D, chain A-B) 
911.0  1003.6 1914.6 0.72 
JIP4-LZII:Arf6-GTP  






2002 PDE:Arl2-GTP  
(PDB 1KSH, chain A-B) 
788.7 809.6 1598.3 0.71 
2003 GRIP:Arl1-GTP  
(PDB 1UPT, chain A-B) 
644.0  652.3 1296.3 0.66 
2003 GGA1GAT:Arf1-GTP 
 (PDB 1J2J, chain A-B) 
588.9 619.2 1208.1 0.70  
 cMKLP1 cMKLP1   
cMKLP1:cMKLP1 
(chain B-D) 
1035.1 1045.3 2080.4 0.78 
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Table S2. Data collection and refinement statistics 
Highest resolution shell is shown in parentheses. Numbers in parentheses indicate values for the 
highest resolution shell. I/σ is the mean reflection intensity divided by the average estimated error. 
Dataset Native (AR-NW12A) Se-Met (BL-5A) 
Data collection   
Space Group P21 P21 
Cell dimensions   
a, b, c (Å) 45.7, 174.6, 76.8 40.8, 173.2, 45.9 
α, β, γ (°) 90.0, 98.7, 90.0 90.0, 111.4, 90.0 
Wavelength (Å) 1.0000  0.9788 
Resolution (Å) 50.00-2.80 50.00-2.54 
Rmerge 0.115 (0.837) 0.098 (0.414) 
I/σ 15.4 (1.7) 13.6 (2.2) 
Completeness (%) 99.9 (99.6) 90.1 (86.7) 
Redundancy 4.2 (3.9) 2.9 (2.3) 
Refinement   
Resolution (Å) 30.00-3.0 50.00-2.54 
No. reflections 22575 16599 
Rwork / Rfree 0.190/0.221 0.235/0.282 
No. atoms   
Protein 8486 4273 
Water 105  
B-factors   
Protein (average) 55.0  43.1 
Arf6 55.7  
cMKLP1 54.4  
water 45.2  
R.m.s deviation   
Bond length (Å) 0.008 0.010  
Bond angles (°) 1.076 1.413 
Ramachandran plot   
Favored (%) 98.2 97.2 
Allowed (%) 1.8 2.4 
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Supplementary Movie Legends 
Movie S1. Spatiotemporal changes in the localization of Arf6-EGFP during cell division 
HeLa cells transfected with an expression vector for Arf6-EGFP were subjected to 
three-dimensional time-lapse recording. Left and right movies, rotated by 90° with respect to the z axis, 
show the same two cells (indicated by yellow and magenta asterisks in Figure 1C). Images were 
collected sequentially every 5 min; the video frame rate is 12 frames/sec. 
 
Movie S2. Three-dimensional image analysis of Arf6-EGFP localization around the cleavage 
furrow 
HeLa cells expressing Arf6-EGFP were fixed and subjected to three-dimensional image 
analysis. A representative cell image with Arf6-EGFP signals at the cleavage furrow is shown. Note 
that the Arf6-EGFP signals appear to be in the cortical region of the cleavage plane, rather than on the 
central spindle. 
 
Movie S3. Spatiotemporal changes in the localization of Arf6-EGFP and mRFP-MKLP1 during 
cell division 
HeLa cells transfected with expression vectors for Arf6-EGFP and mRFP-MKLP1 were 
subjected to time-lapse recording. Images were collected sequentially every 5 min; the video frame 
rate is 3 frames/sec. Note that an MKLP1 signal in the lower dividing cell may represent a Flemming 
body remnant carried over from the previous cell division. 
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